CGEN (Compugen) Market Value to Book Value Ratio

Official company branding of Compugen Ltd (CGEN)

Compugen Ltd. (CGEN) focuses on developing advanced antibodies to combat tumors, receiving financial support from pharmaceutical behemoths. This price chart reflects current market quotes, where the indicator stands at 2.01. The business model relies on the full outsourcing of production and testing, allowing the scientific team to minimize capital expenditures and maintain operational flexibility.

cgen.com (CGEN): Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026
Brand item of cgen.com

For Compugen Ltd. (CGEN), whose revenues depend on licensing payments in the absence of its own commercial product, this metric defines the gap between the actual value of net assets and speculative market expectations regarding research success. By analyzing the market-to-book ratio, an investor assesses the relationship between the current market price and the book value, which allows for the identification of business overvaluation and the risk of a sharp capital correction.

Competitor analysis

Market Value to Book Value Ratio ImmunityBio, Inc.|IMCR (immunocore.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio JANX (Janux Therapeutics, Inc.)|Market-to-Book Ratio RCUS|Market Value to Book Value Ratio Zymeworks Corp ZYME|Capitalization to Book Value Ratio Tango Therapeutics Corp (TNGX)|Iovance Biotherapeutics - Market Capitalization to Book Value Ratio|immatics.com - Market Cap to Net Assets Ratio|XNCR (Xencor) - Market Value to Book Value Ratio|CMPX: Market-to-Book Ratio|Replimune Corp (REPL) - Market Value to Book Value Ratio|LYEL (Lyell Pharma) - Market Value to Book Value Ratio|Market Value to Book Value Ratio IPHA (Innate Pharma S.A.)|Market-to-Book Ratio Pyxis|IOBT: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Sutro Biopharma Inc. STRO|INKT: Market Cap to Net Assets Ratio|HOWL - Market-to-Book Ratio|Market Cap to Net Assets Ratio Immix (IMMX)|ALXO - Market Value to Book Value|Cue Biopharma - Market Capitalization to Book Value Ratio|PDSB (PDS Biotechnology Corporation) - Market Capitalization to Book Value|Market Value to Book Value Ratio SONN|Market Cap to Net Assets Ratio MAIA|Market Value to Book Value Ratio LIMN (Liminatus Pharma)|Market Cap to Net Assets Ratio lavatherapeutics.com LVTX|Market Cap to Net Assets Ratio NXTC (NextCure)|Leap Therapeutics Inc - Market Capitalization to Book Value Ratio|Intensity Tx (INTS) - Market Value to Book Value Ratio|SNSE: Capitalization to Book Value Ratio|Market Value to Book Value Ratio TOVX|Market-to-Book Ratio Gritstone bio|Kineta - Market Cap to Net Assets Ratio|Market Value to Equity Ratio NexImmune Inc (NEXI)|Market Cap to Net Assets Ratio Turnstone Biologics|Market Cap to Book Value Multiple Vaccinex Inc (VCNX)|Market Capitalization to Book Value Ratio Harpoon Therapeutics